MS-PPOH is a potent and specific cytochrome P450 (CYP) cyclooxygenase inhibitor. MS-PPOH inhibits CYP2C8 and CYP2C9 with IC50 of 15 and 11 μM, respectively. MS-PPOH is a reagent for click chemistry. It contains Alkyne groups and could undergo CuAAc (copper-catalyzed azide-alkyne cycloaddition reaction) with compounds bearing an Azide group.

Physicochemical Properties

Molecular Formula	C16H21NO4S
Molecular Weight	323.41
Exact Mass	327.15
CAS #	206052-02-0
PubChem CID	10087567
Appearance	White to off-white solid powder
Density	1.1±0.1 g/cm3
Index of Refraction	1.517
LogP	3.16
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	4
Rotatable Bond Count	9
Heavy Atom Count	22
Complexity	486
Defined Atom Stereocenter Count	0
InChi Key	REUHFEYPDFRRGJ-UHFFFAOYSA-N
InChi Code	InChI=1S/C16H21NO4S/c1-3-13-21-15-11-8-7-10-14(15)9-5-4-6-12-16(18)17-22(2,19)20/h1,7-8,10-11H,4-6,9,12-13H2,2H3,(H,17,18)
Chemical Name	N-methylsulfonyl-6-(2-prop-2-ynoxyphenyl)hexanamide
HS Tariff Code	2934.99.9001
Storage	Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light.
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity

Targets	CYP2
ln Vitro	MS-PPOH prevents the formation of EET in cells. MS-PPOH diminishes the 11,12-EET (1.0 μM)-induced cell motility and prevents invasion and migration of basal (tonic) cells[1].
ln Vivo	Dahl salt-resistant rats on 2% NaCl drinking solution had significantly lower renal levels of epoxyeicosatrienoic acids (EETs) after 6 days of treatment with MS-PPOH (20 mg/kg/day, iv)[3].
Cell Assay	Cell Viability Assay[1] Cell Types: PC -3 cells Tested Concentrations: 2.0 and 10.0 μM Incubation Duration: 24 hrs (hours) Experimental Results: Inhibited tonic (basal) cell invasion and migration.
Animal Protocol	Animal/Disease Models: Sixweeks old male stroke-prone spontaneously hypertensive rats (SHRSP)[3] Doses: 20 mg/kg/day Route of Administration: intravenously (iv) Experimental Results: Treatment had negligible effects on systolic blood pressure (SBP) in saline-drinking SHRSP after 1 week, 160 vs. 167 mmHg, or 2 weeks of treatment, 171 vs. 175 mmHg, for vehicle vs. MS-PPOH, respectively.
References	[1]. Inhibition of carcinoma cell motility by epoxyeicosatrienoic acid (EET) antagonists. Cancer Sci. 2010 Dec;101(12):2629-36. [2]. Cytochrome P450 2C24: Expression, Tissue Distribution, High-Throughput Assay, and Pharmacological Inhibition. Acta Pharm Sin B. 2012 Apr;2(2):137-145. [3]. Pharmacological manipulation of arachidonic acid-epoxygenase results in divergent effects on renal damage. Front Pharmacol. 2014 Aug 15;5:187.

Solubility Data

Solubility (In Vitro)

DMSO: 200 mg/mL (618.41 mM)

Solubility (In Vivo)

Solubility in Formulation 1: ≥ 5 mg/mL (15.46 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 50.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 5 mg/mL (15.46 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 50.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 5 mg/mL (15.46 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 50.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.)

Preparing Stock Solutions		1 mg	5 mg	10 mg
	1 mM	3.0921 mL	15.4603 mL	30.9205 mL
	5 mM	0.6184 mL	3.0921 mL	6.1841 mL
	10 mM	0.3092 mL	1.5460 mL	3.0921 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.